Compare Johnson & Johnson (JNJ) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Mesoblast Limited — how do they compare? Johnson & Johnson trades at $250.66 (market cap $598.96B), while Mesoblast Limited trades at $16.38 (market cap $2.17B). The key difference: Johnson & Johnson is far larger — about 276× Mesoblast Limited's market cap, and Johnson & Johnson pays a 2.15% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| JNJ | MESO | |
|---|---|---|
Market Cap | $598.96B | $2.17B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $20.96 |
52-Week Low | $164.36 | $12.88 |
Enterprise Value | $631.90B | $2.17B |
Dividend Yield | 2.15% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
